| 刁维东,王金柱,李永红,汪国琴,柯浩珍,沈存芳.马来酸氟伏沙明片联合氨磺必利治疗精神分裂症患者的疗效及安全性分析[J].现代生物医学进展英文版,2020,(2):357-360. |
| 马来酸氟伏沙明片联合氨磺必利治疗精神分裂症患者的疗效及安全性分析 |
| Analysis of the Clinical Effect and safety of Fluvoxamine Maleate Tablets Combined with Sulfamethoxalide on the Patients with Schizophrenia |
| Received:March 28, 2019 Revised:April 23, 2019 |
| DOI：10.13241/j.cnki.pmb.2020.02.033 |
| 中文关键词: 精神分裂症 马来酸氟伏沙明片 氨磺必利 糖脂代谢 总胆汁酸 |
| 英文关键词: Schizophrenia Fluvoxamine Maleate Tablet Sulfamethoxalide Glycolipid Metabolism Total Bile Acid |
| 基金项目:青海省自然科学基金项目(20140103) |
| Author Name | Affiliation | | DIAO Wei-dong | Pharmacy, Third People's Hospital of Qinghai Province, Xining, Qinghai, 810007, China | | WANG Jin-zhu | Pharmacy, Third People's Hospital of Qinghai Province, Xining, Qinghai, 810007, China | | LI Yong-hong | Pharmacy, Third People's Hospital of Qinghai Province, Xining, Qinghai, 810007, China | | WANG Guo-qin | Pharmacy, Third People's Hospital of Qinghai Province, Xining, Qinghai, 810007, China | | KE Hao-zhen | Department of Blood Transfusion, Qinghai Provincial People's Hospital, Xining, Qinghai, 810007, China | | SHEN Cun-fang | Department of Oncology, Affiliated Hospital of Qinghai University, Xining, Qinghai, 810007, China |
|
| Hits: 818 |
| Download times: 1412 |
| 中文摘要: |
| 摘要 目的：分析马来酸氟伏沙明片联合氨磺必利治疗精神分裂症患者的临床疗效及安全性。方法：选择我院2014年2月~2018年2月收治的182例精神分裂症患者，按随机数字表法分为对照组99例和研究组83例。对照组采用氨磺必利治疗，研究组在对照组基础上联合马来酸氟伏沙明片治疗。比较两组临床疗效，治疗前后血脂代谢、总胆汁酸(TBA)水平，阳性与阴性症状量表(PANSS)评分，生活质量，及不良发生情况。结果：治疗后，研究组总有效率为91.57%，显著高于对照组(P<0.05)；两组治疗前后空腹血糖(FPG)、糖化血红蛋白(HbA1c)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白-C(LDL-C)、高密度脂蛋白-C(HLD-C)、总胆汁酸(TBA)水平比较均无统计学意义(P>0.05)；两组治疗后PANSS评分均较治疗前显著下降，生活质量评分较治疗前均明显上升，且研究组PANSS评分显著低于对照组，而生活质量评分明显高于对照组，差异均有统计学意义(P<0.05)。治疗过程中，两组均有体重增加、口渴及便秘发生，两组不良反应发生情况比较差异无统计学意义(P>0.05)。结论：马来酸氟伏沙明片联合氨磺必利治疗能够提高精神分裂症患者疗效，对机体糖脂代谢及肝功能影响较小，有良好的用药安全性。 |
| 英文摘要: |
| ABSTRACT Objective: To analyze the clinical effect and safety of fluvoxamine maleate tablets combined with sulfamethoxalide on the patients with schizophrenia. Methods: 182 schizophrenic patients who were treated from February 2014 to February 2018 in our hospital were divided into 99 cases in the control group and 83 cases in the research group according to the random number table method. The control group was treated with sulfamethoxalide, and the research group was treated with fluvoxamine maleate tablets on the basis of control group. Then the clinical efficacy, changes of blood lipid metabolism, level of total bile acid (TBA), positive and negative symptom scale (PANSS) score, quality of life before and after treatment and the incidence of adverse events were compared between two groups. Results: After treatment, the total effective rate in the research group was 91.57%, which was significantly higher than that in the control group (P<0.05). The fasting blood glucose (FPG), glycosylated hemoglobin (HbA1c), triglycerides (TG), total cholesterol (TC), low-density lipoprotein C(LDL-c), high-density lipoprotein C(HLD-c), and levels of TBA of both groups showed no statistically significant difference before and after treatment(P>0.05). After treatment, the PANSS scores of both groups were significantly decreased compared with those before treatment, and the quality of life scores were significantly increased compared with those before treatment, The PANSS score in the research group were significantly lower than that in the control group, while the quality of life score was significantly higher than that in the control group(P<0.05). During treatment, the incidence of weight gain, thirst and constipation showed no statistically significant difference between the two groups (P>0.05). Conclusion: Fluvoxamine maleate tablets combined with sulfamethoxalide can improve the curative effect of patients with schizophrenia, it had little effect on the glucose and lipid metabolism and liver function with good drug safety. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
